SELLAS Life Sciences (SLS)

Executive Summary

SELLAS Life Sciences is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting WT1 and HER2/neu. Its lead candidate, galinpepimut-S (GPS), is a WT1-targeting immunotherapy being evaluated in a Phase 3 trial for acute myeloid leukemia (AML) in combination with standard of care, with completion expected in late 2026. GPS has shown promise in earlier studies, demonstrating durable responses in relapsed/refractory AML. Additionally, the company is advancing nelipepimut-S (NPS) for HER2-positive breast cancer, with Phase 2 trials completed. SELLAS also has an early-stage pipeline including SLS009, a CDK9 inhibitor, in Phase 1/2 for hematologic malignancies. The company's valuation reflects the binary risk associated with its late-stage pipeline. Positive Phase 3 GPS data could significantly derisk the platform and expand into other WT1-expressing tumors. However, the company faces competition from other AML therapies and must manage clinical and regulatory risks. Key upcoming catalysts include final data from the Phase 3 GPS trial in 2026 and potential interim analyses. With a focused pipeline and multiple shots on goal, SELLAS presents a speculative but potentially high-reward opportunity in the oncology space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 GPS trial for AML interim data readout40% success
• Q3 2026Phase 1/2 SLS009 combo trial data update50% success
• Q3 2026Potential partnership or licensing deal for GPS or NPS30% success